Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$33.35 – $41.40
63% from low
No one on the platform currently holds RAYD.
No tracked institution reports a position in RAYD as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-12-30 | $0.3111 | 2025-01-07 |
| 2023-12-28 | $0.4055 | 2024-01-05 |
No one on the platform has traded RAYD yet.
| +1.06% |
| $104M |
| — |
| GSEUGoldman Sachs ActiveBeta Europe Equity ETF | $48.28 | +0.92% | $118M | — |
| RAYERayliant Quantamental Emerging Market Equity ETF | $29.00 | -1.26% | $78M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$RAYD Confidence will depend on whether guidance becomes dependable; balance‑sheet optionality should not erode — measurable traction would outweigh rhetoric. Only demonstrated reliability will sustain upside potential.
View on StockTwits ↗Lowest Volume Rated ETFs Per 12/5/2024’s Close: 1 – $SEPT 2 – $ZTWO 3 – $OVT 4 – $ZTRE 5 – $USCA 6 – $BHYB 7 – $XSMO 8 – $RAYD 9 – $CCNR 10 – $SPTB https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-12-5-2024/
View on StockTwits ↗Lowest Volume Rated ETFs Per 10/18/2024’s Close: 1 – $SECR 2 – $XHYT 3 – $UNIY 4 – $MDLV 5 – $RAYD 6 – $MVFD 7 – $PSMR 8 – $CTEX 9 – $WEIX 10 – $SHUS https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-10-18-2024/
View on StockTwits ↗Mid-Day Top 5 Gainers Report: $WEYS (0%) $RAYD (0%) $SQSP (0%) $SPHQ (0%) $HYGW (0%) If we missed a split/reverse split, let us know!
View on StockTwits ↗Rayliant Quantamental China Equity ETF Surpasses $100 Million in AUM $RAYC $RAYD $RAYE https://newsfilter.io/a/14e2b22f368b47f3c727e847ce7b897e
View on StockTwits ↗$ATER $JSPR $CEIN $MYSE $RAYD INM is at a 52 week low of $1.40. It has a price target of $24. It has a super low float with tons of cash on hand until 2023. They just acquired baymedica which will manufacture and commercialize all products for INM. INM is the future world leader of rare cannabinoids medicine. They are really oversold and ready to explode. Please add INM to your watchlist. Thanks!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.